Related Experiment Video

Updated: Apr 19, 2026

Implantation of the Syncardia Total Artificial Heart
16:11

Implantation of the Syncardia Total Artificial Heart

Published on: July 18, 2014

36.3K

Uncovering the cathepsin system in heart failure patients submitted to Left Ventricular Assist Device (LVAD)

Andrea D'Amico1, Rosetta Ragusa2, Raffaele Caruso3

  • 1Scuola Superiore Sant'Anna, Institute of Life Sciences, 56100, Pisa, Italy. andrea.damico@ifc.cnr.it.

Journal of Translational Medicine
|December 16, 2014
PubMed

Insights

Left ventricular assist device (LVAD) implantation increases cathepsin levels in heart failure patients, impacting cardiac remodeling. Understanding these protease pathways may improve patient outcomes.

Area of Science:

  • Cardiology
  • Biochemistry
  • Protease research

Background:

  • End-stage heart failure (HF) can be treated with left ventricular assist devices (LVADs), which promote reverse cardiac remodeling.
  • Cellular proteases, particularly cathepsins, are implicated in HF progression.
  • The role of the cathepsin system in LVAD-supported HF patients and its relation to cardiac remodeling requires further investigation.

Purpose of the Study:

  • To investigate the expression and role of the cathepsin system in patients with end-stage heart failure undergoing LVAD support.
  • To determine if LVAD implantation influences cathepsin activity and cardiac remodeling.
  • To explore correlations between cathepsin expression, clinical factors, and patient outcomes.

Main Methods:

  • Cardiac biopsies were analyzed from 22 LVAD patients (pre-LVAD) and compared to heart transplant (HT) patients (n=7) and post-LVAD transplant patients (n=6).
  • Expression levels of cysteine cathepsins (CatB, CatK, CatL, CatS), serine cathepsin (CatG), and their inhibitors (Cystatin B, C, SerpinA3) were quantified.
  • Statistical analyses identified correlations between cathepsin expression, inflammatory cytokines, clinical etiology, and hospitalization duration.

Main Results:

  • Cathepsin and inhibitor expression were significantly elevated in pre-LVAD patients compared to HT controls.
  • LVAD support led to a further increase in the cathepsin system.
  • Positive correlations were found between cardiac cathepsin/inhibitor expression and inflammatory cytokines, dilatative etiology, and hospitalization length.

Conclusions:

  • LVAD support is associated with parallel activation of cathepsins and their endogenous inhibitors.
  • These observed modifications in the cathepsin system correlate with patient outcomes, suggesting clinical significance.
  • Further research into these pathways could provide deeper insights into cardiac remodeling mechanisms in HF.
Abstract

More Related Videos

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

4.3K
Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

7.2K

Related Concept Videos

Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
724
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
811
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
812
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
614
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
1.6K
Cardiac Catheterization III: Left Heart Catheterization01:24

Cardiac Catheterization III: Left Heart Catheterization

Left heart catheterization is an invasive diagnostic procedure used to evaluate the function and structure of the left side of the heart. It is generally performed to diagnose and treat cardiovascular conditions such as valve abnormalities, coronary artery disease, and congenital heart defects.Diagnostic and therapeutic purposesLeft heart catheterization serves various diagnostic and therapeutic purposes, including:Assessing coronary artery bypass grafts.Evaluating coronary artery disease in...
1.3K